Ketotic hypercalcemia: A case series and description of a novel entity

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1531-1536

  Hawkes, Colin Patrick ^a,b   Levine, Michael A ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NATIONAL CHILDREN S RESEARCH CENTRE   (Ireland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BICARBONATE; CALCITONIN; CALCITRIOL; CALCIUM; CREATININE; ETHOSUXIMIDE; ETIRACETAM; HARKOSERIDE; PARATHYROID HORMONE; PHENOBARBITAL; PHOSPHATE; TOPIRAMATE; VALPROATE SEMISODIUM; VITAMIN D;

ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALCIUM URINE LEVEL; CASE REPORT; CEREBRAL CORTEX DYSPLASIA; CHILD; CHROMOSOME DELETION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DYSPLASIA; EPILEPSY; HUMAN; HYPERCALCEMIA; KETOGENIC DIET; KETOTIC HYPERCALCEMIA; MALE; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; VITAMIN INTAKE;

BONE AND BONES; CALCIUM, DIETARY; CHILD, PRESCHOOL; HUMANS; HYPERCALCEMIA; KETOGENIC DIET; MALE; SEIZURES;

EID: 84899964293     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4275     Document Type: Article

References (29)

1. Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol Scand. 1999;99:269-275.
2. Khanna S, Pillai KK, Vohora D . Insights into liaison between antiepileptic drugs and bone. Drug Discov Today. 2009;14:428-435.
3. Levine MA. Assessing bone health in children and adolescents. Indian J Endocrinol Metab. 2012;16:S205-212.
4. Guelpa GM. La lutte contre l'épilepsie par la dé sintoxication et par la rééducation alimentaire. Revue de Therapie Medico-Chirurgicale. 1911;78:8-13.
5. Politi K, Shemer-Meiri L, Shuper A, Aharoni S. The ketogenic diet 2011: how it works. Epilepsy Res Treat. 2011;2011:963637.
6. Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia. 2007;48:43-58.
7. Wang HS, Lin KL. Ketogenic diet: an early option for epilepsy treatment, instead of a last choice only. Biomed J. 2013;36:16-17.
8. Kossoff EH Rho JM. Ketogenic diets: evidence for short-and longterm efficacy Neurotherapeutics. 2009 6 406-414.
9. Kang HC, Chung DE, Kim DW, Kim HD. Early-and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004;45:1116-1123.
10. Keene DL. A systema tic review of the use of the ketogenic diet in childhood epilepsy. Pediatr Neurol. 2006;35:1-5.
11. McNally MA, Pyzik PL, Rubenstein JE, Hamdy RF, Kossoff EH. Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. Pediatrics. 2009;124:e300-e304.
12. Hahn TJ, Halstead LR, DeVivo DC. Disordered mineral metabolism produced by ketogenic diet therapy. Calcif Tissue Int. 1979; 28:17-22.
13. Bergqvist AG, Schall JI, Stallings VA, Zemel BS. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr. 2008;88:1678-1684.
14. Furth SL, Casey JC, Pyzik PL, et al. Risk factors for urolithiasis in children on the ketogenic diet. Pediatr Nephrol. 2000;15:125-128.
15. Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP. Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr. 199 7;131:252-257.
16. Danial NN, Hartman AL, Stafstrom CE, Thio LL. How does the ketogenic diet work Four potential mechanisms. J Child Neurol. 2013;28:1027-1033.
17. Greene RW. Adenosine: front and center in linking nutrition and metabolism to neuronal activity. J Clin Invest. 2011;121:2548-2550.
18. Masino SA, Li T, Theofilas P, et al. A ketogenic diet suppresses seizures in mice through adenosineA1 receptors. J Clin Invest. 2011; 121:2679-2683.
19. Ham J, Evans BA. An emerging role for adenosine and its receptors in bone homeostasis. Front Endocrinol (Lausanne). 2012;3:113.
20. Mediero A, Cronstein BN. Adenosine and bone metabolism. Trends Endocrinol Metab. 2013;24:290-300.
21. Mediero A, Kara FM, Wilder T, Cronstein BN. Adenosine A(2A) receptor ligation inhibits osteoclast formation. Am J Pathol. 2012; 180:775-786.
22. Gharibi B, Abraham AA, Ham J, Evans BA. Contrasting effects of A1andA2badenosine receptors on adipogenesis. Int J Obes (Lond). 2012;36:397-406.
23. HongR. Associations of the skeletal and immune systems.AmJMed Genet. 1989;34:55-59.
24. Sauer AV, Mrak E, Hernandez RJ, et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype cha racterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood. 2009;114:3216-3226.
25. Brandao-Burch A, Utting JC, Orriss IR, Arnett TR. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int. 2005;77:167-174.
26. Kato K, Matsushita M. Proton concentrations can be a major contributor to the modification of osteoclast and osteoblast differ entiation, working independently of extracellular bicarbonate ions. J Bone Miner Metab. 2014;32:17-28.
27. Pereverzev A, Komarova SV, Korcok J, et al. Extracellular acidification enhances osteoc last survival through an NFAT-independent, protein kinase C-dependent pathway. Bone. 2008;42:150-161.
28. Sampath A, Kossoff EH, Furth SL, Pyzik PL, Vining EP. Kidney stones and the ketogenic diet: risk factors and prevention. J Child Neurol. 2007;22:375-378.
29. Kossoff EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: recomme ndations of the International Ketogenic Diet Study Group. Epilepsia. 2009;50:304-317. Kidney Diseases